List view / Grid view
The European Medicines Agency (EMA) has published an action plan that aims to foster innovation and support small and medium-sized enterprises (SMEs) in the development of novel human and veterinary medicines.
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
In 2018, industry leaders from pharma, biotech and clinical research organisations will advance the participation of patients in clinical trials...
SmartAction and EndPoint Technologies have formed a strategic partnership to expand the availability of AI-powered customer technology.
Lab Innovations – the UK’s only dedicated showcase for laboratory technology, analytical and biotech equipment – returns for its sixth consecutive year on 1 & 2 November 2017 at the NEC, Birmingham...
A key session opens up the challenges of delivering personalized genetic medicines...
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
A new report released by the UK BioIndustry Association (BIA) shows that the UK maintained its strong leadership position in European biotech funding last year and has the strongest pipeline in Europe for future drug development.
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
Primary sclerosing cholangitis is a currently incurable liver disorder, primarily affecting younger adults aged between 30 and 40.
In the first large pragmatic trial of its kind in the United States, results from a study show that checking finger-stick blood sugars may not help diabetes patients who do not use insulin.
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
Health leaders announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.
The FDA has granted fast track designation for Pfizer and Eli Lilly’s tanezumab for the treatment of chronic pain in patients with osteoarthritis...
